Argonaute-2 autoantibodies: a promising biomarker for predicting mortality in HBV-related acute-on-chronic liver failure patients with cirrhosis
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1407064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Yixuan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis…. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Argonaute Proteins, Autoantibodies, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Medical University.
Abstract (Originalsprache)
Background & aims HBV infection initiates autoimmune responses, leading to autoantibody generation. This research explores the role of autoantibodies in HBV-related Acute-on-Chronic Liver Failure (ACLF), offering novel perspectives for clinical management.
Method
We applied immunoprecipitation and iTRAQ techniques to screen for autoantibodies in serum from HBV-related cirrhosis patients and conducted detection with conformation- stabilizing ELISA in a cohort of 238 HBV-infected individuals and 49 health controls. Our results were validated in a retrospective cohort comprising 106 ACLF patients and further assessed through immunohistochemical analysis in liver tissues from an additional 10 ACLF cases.
Results
Utilizing iTRAQ, we identified Argonaute1-3 autoantibodies (AGO-Abs) in this research. AGO2-Abs notably increased in cirrhosis, decompensation, and further in ACLF, unlike AGO1-Abs and AGO3-Abs. This reflects disease severity correlation. Logistic regression and COX models confirmed AGO2-Abs as independent prognostic indicators for decompensated liver cirrhosis (DLC) and ACLF. In the ROC analysis, AGO2-Abs showed significant diagnostic value for predicting 28- and 90-day mortality (AUROC = 0.853 and 0.854, respectively). Furthermore, combining AGO2-Abs with the Child-Pugh, MELD, and AARC scores significantly improved their predictive accuracy (P < 0.05). Kaplan-Meier analysis showed poorer survival for AGO2-Abs levels above 99.14μg/ml. These findings were supported by a retrospective validation cohort. Additionally, immunohistochemistry revealed band-like AGO2 expression in periportal liver areas, with AGO2-Abs levels correlating with total bilirubin, indicating a potential role in exacerbating liver damage through periportal functions.
Conclusions
AGO2-Abs is a robust biomarker for predicting the mortality of patients with HBV-related ACLF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongq…
- Department of Vascular Surgery, Chongqing Medical University, Chongqing, China.
- Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
- Central Laboratory, Chongqing University FuLing Hospital, Chongqing, China.
Förderung
- Chongqing Medical University
Zitieren
APA
Wang, Y., Hu, Y., Li, J., Ma, H., Shi, Z., Wen, C., Long, Y., Li, Z., Sun, H., Yang, Y., & Shi, X. (2024). Argonaute-2 autoantibodies: a promising biomarker for predicting mortality in HBV-related acute-on-chronic liver failure patients with cirrhosis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1407064
Vancouver
Wang Y, Hu Y, Li J, Ma H, Shi Z, Wen C, et al. Argonaute-2 autoantibodies: a promising biomarker for predicting mortality in HBV-related acute-on-chronic liver failure patients with cirrhosis. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1407064
BibTeX
@article{Wang2024,
author = {Wang, Yixuan and Hu, Yue and Li, Jiaqi and Ma, Huailu and Shi, Zongqi and Wen, Chaojing and Long, Yu and Li, Ziwei and Sun, Hang and Yang, Yixuan and Shi, Xiaofeng},
title = {Argonaute-2 autoantibodies: a promising biomarker for predicting mortality in HBV-related acute-on-chronic liver failure patients with cirrhosis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1407064}
}
EUVIMED